CTI BioPharma

• NCT07387354

  Collaborator, Phase 1/2, Withdrawn, 0 people, 4 Feb 2026

• NCT02891603

  Collaborator, Phase 1/2, Completed, 40 people, 7 Sept 2016

• NCT02564536

  Collaborator, Phase 1, Withdrawn, 0 people, 30 Sept 2015

• NCT02469415

  Collaborator, Phase 2, Terminated, 3 people, 11 Jun 2015

• NCT02323607

  Collaborator, Phase 1, Completed, 13 people, 23 Dec 2014

• NCT01227408

  Collaborator, Phase 2, Withdrawn, 0 people, 25 Oct 2010

• NCT00661544

  Collaborator, Phase 1/2, Completed, 48 people, 18 Apr 2008

• NCT00576225

  Phase 3, Withdrawn, 0 people, 19 Dec 2007

• NCT00551733

  Phase 3, Terminated, 450 people, 31 Oct 2007

• NCT00352690

  Collaborator, Phase 2, Terminated, 10 people, 17 Jul 2006

• NCT00291785

  Phase 1/2, Completed, 48 people, 15 Feb 2006

• NCT00269828

  Phase 3, Terminated, 600 people, 26 Dec 2005

• NCT00088530

  Phase 3, Completed, 140 people, 29 Jul 2004

• NCT00069901

  Phase 2, Completed, 82 people, 6 Oct 2003

• NCT00060684

  Phase 1, Completed, 30 people, 12 May 2003

• NCT00054210

  Phase 3, Terminated, 6 Feb 2003

• NCT00017069

  Phase 2, Terminated, 27 Jan 2003

• Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

  Fees or honoraria, 12 Jan 2026

Sources: pubmed.ncbi.nlm.nih.gov